---
title: "LINC 2024: C-GUARDIANS data represent lowest event rates in published trials of CAS, TCAR and CEA"
date: "2024-05-28T14:15:15.000Z"
publishedDate: "28 mai 2024"
summary: "New data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial support consideration of carotid artery stenting (CAS) with the CGuard embolic prevention stent system (EPS; InspireMD) as a &#8220;frontline therapeutic option for appropriate patients being considered for carotid revascularisation&#8221;. This is according to lead investigator Chris Metzger (OhioHealth, Columbus, USA), who presented one-year results [&#8230;] The post LINC 2024: C-GUARDIANS data represent lowest event rates in published trials of CAS, TCAR and CEA appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/linc-2024-c-guardians-data-represent-lowest-event-rates-in-published-trials-of-cas-tcar-and-cea/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2024-05-28-linc-2024-c-guardians-data-represent-lowest-event-rates-in-published-trials-of-cas-tcar-and-cea"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2024/05/Chris-Metzger.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/linc-2024-c-guardians-data-represent-lowest-event-rates-in-published-trials-of-cas-tcar-and-cea/"
---

![LINC 2024: C-GUARDIANS data represent lowest event rates in published trials of CAS, TCAR and CEA](https://vascularnews.com/wp-content/uploads/sites/7/2024/05/Chris-Metzger.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/linc-2024-c-guardians-data-represent-lowest-event-rates-in-published-trials-of-cas-tcar-and-cea/*

## L’essentiel

New data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial support consideration of carotid artery stenting (CAS) with the CGuard embolic prevention stent system (EPS; InspireMD) as a &#8220;frontline therapeutic option for appropriate patients being considered for carotid revascularisation&#8221;. This is according to lead investigator Chris Metzger (OhioHealth, Columbus, USA), who presented one-year results [&#8230;] The post LINC 2024: C-GUARDIANS data represent lowest event rates in published trials of CAS, TCAR and CEA appeared first on Vascular News .

## Lien source

https://vascularnews.com/linc-2024-c-guardians-data-represent-lowest-event-rates-in-published-trials-of-cas-tcar-and-cea/
